MAPT and Cognitive impairment: Previously, we reported significant reductions in 4 esterified proresolving oxylipins in 10-month-old TgF344-AD rats (59), prior to the onset of cognitive impairment, neuroinflammation, and plaque and phosphorylated tau accumulation (60).